Does Anthem (Elevance Health) Cover Amlodipine?

How Anthem (Elevance Health) Covers Amlodipine

Generic amlodipine besylate is covered on virtually all Anthem (Elevance Health) commercial, Medicare Advantage, and Medicaid managed-care formularies. Because the drug lost patent exclusivity in 2007, generic competition has driven its retail cost well below most specialty thresholds, and Anthem classifies it as a preferred generic on the majority of plan designs.

Coverage extends to all three FDA-approved indications: hypertension, chronic stable angina, and vasospastic (Prinzmetal) angina [1]. Anthem does not typically impose quantity limits on standard doses (2.5 mg, 5 mg, or 10 mg once daily), and most plans allow a 90-day mail-order fill at reduced copay rates. The drug's inclusion on preferred generic tiers reflects both its low acquisition cost and the strong evidence base supporting calcium channel blockers as first-line antihypertensives. The 2017 ACC/AHA Hypertension Guideline lists amlodipine among four first-line drug classes recommended for stage 1 and stage 2 hypertension in adults [2].

Brand-name Norvasc is a different story. Anthem typically places Norvasc on Tier 2 (preferred brand) or Tier 3 (non-preferred brand), depending on the specific plan. Some Anthem plans require prior authorization or a documented trial-and-failure of the generic before covering the brand at a preferred rate.

Formulary Tier Placement for Amlodipine on Anthem Plans

Anthem operates multiple formulary lists across its commercial, exchange, Medicare Part D, and Medicaid product lines. Tier placement varies by plan, but the general pattern is consistent.

Commercial PPO and HMO plans. Generic amlodipine sits on Tier 1. Copays range from $0 on some high-premium plans to $15 on standard designs. A 90-day supply through Anthem's preferred mail-order pharmacy (typically CVS Caremark or Express Scripts, depending on the plan year) may reduce the per-fill cost by 20% to 40%.

Anthem Blue Cross Medicare Advantage (Part D). Generic amlodipine appears on Tier 1 of the Part D formulary. During the initial coverage phase, Medicare beneficiaries can expect copays of $0 to $5 for a 30-day generic fill. Amlodipine is not subject to the coverage gap ("donut hole") penalty that applies to higher-tier medications [3].

Medicaid managed care. Anthem's Medicaid plans in states like Indiana, Ohio, and Virginia list amlodipine as a preferred drug with $0 to $3 copays, consistent with federal Medicaid rebate requirements.

To confirm your specific tier placement, log in to the Anthem member portal at anthem.com, select "Find a Medication," and enter "amlodipine." The result will display your plan's tier, copay, and any utilization management flags.

Prior Authorization and Step Therapy Requirements

Generic amlodipine does not require prior authorization on standard Anthem commercial formularies. This is expected for a medication that the ACC/AHA 2017 Guideline recommends as one of four first-line antihypertensive classes alongside thiazide diuretics, ACE inhibitors, and ARBs [2]. Anthem's pharmacy benefit managers recognize amlodipine as a guideline-concordant initial therapy, so utilization controls would conflict with current evidence.

However, prior authorization may apply in specific circumstances. If a prescriber writes for brand Norvasc instead of generic amlodipine, Anthem will often require documentation that the generic is medically inappropriate (for example, a documented allergy to a specific inactive ingredient in the generic formulation). A prescriber must submit a Coverage Review Request through Anthem's online provider portal or by fax.

Step therapy is not typically required before starting amlodipine. The opposite situation is more common: Anthem may require a trial of amlodipine (or another first-line agent) before covering more expensive antihypertensives such as brand-name ARB/CCB combinations. In the ALLHAT trial (N=33,357), the amlodipine arm showed comparable primary outcomes to the chlorthalidone arm for fatal coronary heart disease and nonfatal myocardial infarction, which supports its position as an acceptable first-step agent [4].

Some Anthem Medicare Advantage plans do apply step therapy for combination products containing amlodipine (such as amlodipine/benazepril or amlodipine/valsartan). These plans typically require documentation that the patient tried the individual components separately before approving the fixed-dose combination.

What Amlodipine Costs on Anthem Plans

The cost of amlodipine on an Anthem plan depends on your formulary tier, pharmacy choice, and whether you opt for a 30-day or 90-day fill.

With Anthem insurance (generic amlodipine):

• Tier 1 copay, retail pharmacy: $0 to $15 per 30-day supply
• Tier 1 copay, mail-order 90-day supply: $0 to $25
• Deductible phase (high-deductible plans): $4 to $12, since the cash price is often lower than the deductible copay

With Anthem insurance (brand Norvasc):

• Tier 2 or Tier 3 copay: $30 to $75 per 30-day supply
• Manufacturer list price: approximately $80 per month for 30 tablets

Without insurance (cash pay):

• Generic amlodipine 5 mg, 30 tablets: $4 to $12 at most retail pharmacies
• GoodRx or RxSaver discount: as low as $3 at select pharmacies

Generic amlodipine is one of the least expensive prescription medications in the United States. Many pharmacy chains (Walmart, Costco, Kroger) include it on $4 generic lists. For patients on Anthem high-deductible health plans (HDHPs), the cash price may actually be lower than the negotiated insurance rate during the deductible phase. Ask your pharmacist to run both the insurance price and the cash price at the register. This takes 30 seconds and can save you money.

The ASCOT-BPLA trial (N=19,257) demonstrated that amlodipine-based therapy reduced all-cause mortality by 11% compared to atenolol-based therapy over a median 5.5-year follow-up, a clinical benefit that costs less than a monthly streaming subscription at generic pricing [5].

How to Appeal an Anthem Denial for Amlodipine

Denials for generic amlodipine are rare but not impossible. They most commonly occur when a plan has a narrow formulary, when the claim is processed incorrectly, or when a prescriber inadvertently writes for brand Norvasc without specifying "dispense as written" for a medically necessary reason.

Step 1: Understand the denial reason. Anthem sends an Explanation of Benefits (EOB) or a pharmacy rejection code at the point of sale. Common rejection codes include "prior authorization required" (PA), "non-formulary" (NF), or "step therapy required" (ST). Read the specific language.

Step 2: File a first-level internal appeal. Anthem allows 180 days from the denial date to file an internal appeal. You or your prescriber can submit the appeal online through the Anthem provider or member portal, by fax, or by mail. Include the prescriber's letter of medical necessity, relevant lab results (such as blood pressure readings), and documentation of any prior medication trials.

For amlodipine specifically, citing the 2017 ACC/AHA Hypertension Guideline recommendation as a first-line agent strengthens the appeal [2]. If the denial involves brand Norvasc, include documentation of adverse reactions to generic formulations or a pharmacist's confirmation that no therapeutically equivalent generic is available.

Step 3: Request an external review. If Anthem upholds the denial on internal appeal, you have the right to an independent external review through your state's insurance department or an accredited Independent Review Organization (IRO). Under the Affordable Care Act's external review provisions, the IRO's decision is binding on Anthem [6]. External reviews are free to the member in most states.

Anthem must process standard internal appeals within 30 days. Expedited appeals (for urgent clinical situations) must be resolved within 72 hours. If your blood pressure is uncontrolled and you need the medication immediately, request an expedited appeal and ask your prescriber to call Anthem's clinical review line directly.

Amlodipine Compared to Other Covered Antihypertensives on Anthem

Anthem formularies cover all four first-line antihypertensive classes recommended by the ACC/AHA. Choosing between them depends on clinical factors, not just cost.

Amlodipine vs. lisinopril (ACE inhibitor). Both are Tier 1 generics on Anthem. The ACCOMPLISH trial (N=11,506) found that amlodipine plus benazepril reduced cardiovascular events by 19.6% compared to benazepril plus hydrochlorothiazide [7]. Amlodipine may be preferred in Black patients, where calcium channel blockers show stronger blood-pressure-lowering effects than ACE inhibitors as monotherapy, per ALLHAT subgroup data [4].

Amlodipine vs. losartan (ARB). Generic losartan is also Tier 1 on most Anthem plans. ARBs are often chosen when patients develop the dry cough associated with ACE inhibitors. The VALUE trial (N=15,245) compared valsartan to amlodipine and found similar cardiac outcomes but better blood pressure control in the amlodipine group during the first six months [8].

Amlodipine vs. hydrochlorothiazide (thiazide diuretic). Hydrochlorothiazide is the cheapest option, often $4 or less for a 30-day supply. For patients without compelling indications for a specific drug class, either agent is acceptable. Amlodipine does not cause the electrolyte disturbances (hypokalemia, hyponatremia) associated with thiazides, which may reduce the need for monitoring labs.

Dr. Paul Whelton, lead author of the 2017 ACC/AHA Guideline, has stated: "The choice among first-line agents should be individualized based on comorbidities, potential adverse effects, drug interactions, and patient preference" [2].

Clinical Evidence Behind Amlodipine Formulary Placement

Insurance formulary committees evaluate clinical trial data when deciding tier placement. Amlodipine's position as a Tier 1 preferred generic reflects decades of outcomes evidence.

The ASCOT-BPLA trial randomized 19,257 patients with hypertension and at least three cardiovascular risk factors to amlodipine-based or atenolol-based therapy. The amlodipine arm showed a 23% reduction in fatal and non-fatal stroke, a 24% reduction in cardiovascular events, and an 11% reduction in all-cause mortality [5]. The trial was stopped early because of the clear benefit in the amlodipine group. These results contributed to a broad shift away from beta-blockers as first-line antihypertensives in guidelines worldwide.

The CAMELOT trial (N=1,991) demonstrated that amlodipine 10 mg reduced cardiovascular events by 31% compared to placebo in patients with coronary artery disease and normal blood pressure (mean baseline BP 129/78 mmHg), with intravascular ultrasound showing a trend toward reduced atherosclerosis progression [9]. This finding supports amlodipine's dual utility in both hypertension and stable angina.

Long-term safety data spanning more than 30 years of post-marketing surveillance confirm that amlodipine's most common adverse effects are peripheral edema (occurring in approximately 8.3% of patients at the 10 mg dose), dizziness (3.4%), and flushing (2.6%) [1]. These effects are dose-dependent and reversible upon discontinuation.

Amlodipine carries a unique pharmacokinetic advantage among calcium channel blockers. Its plasma half-life of 30 to 50 hours allows true once-daily dosing with minimal blood pressure variability, a property that may improve adherence compared to shorter-acting agents [1]. For patients on Anthem plans filling a 90-day mail-order supply, this means a single tablet taken at any consistent time of day with no need for twice-daily dosing.

Special Populations and Anthem Coverage Considerations

Anthem applies the same formulary tier for amlodipine regardless of indication, but prescribers should be aware of coverage nuances for specific patient groups.

Pregnancy. Amlodipine is classified as pregnancy category C. Anthem does not restrict coverage based on pregnancy status, but the ACOG Practice Bulletin on chronic hypertension in pregnancy recommends nifedipine (another dihydropyridine CCB) as the preferred calcium channel blocker during pregnancy due to more extensive safety data [10]. Both generics are Tier 1 on Anthem.

Pediatric patients. The FDA approved amlodipine for hypertension in children aged 6 to 17 years at doses of 2.5 mg to 5 mg daily [1]. Anthem covers pediatric prescriptions under the same tier structure. Quantity limits are the same as for adults.

Renal impairment. No dose adjustment is required. Amlodipine is hepatically metabolized, and its pharmacokinetics are not significantly altered by renal dysfunction [1]. This is an advantage over ACE inhibitors and ARBs, which require dose adjustments at low GFR values.

Elderly patients. The ACC/AHA Guideline recommends initiating amlodipine at 2.5 mg in adults aged 65 and older, titrating based on response [2]. Anthem does not impose age-based prior authorization or quantity restrictions. The HYVET trial (N=3,845) showed that antihypertensive treatment in patients aged 80 and older reduced stroke by 30% and all-cause mortality by 21%, supporting active treatment in this age group [11].